The combination test will allow clinicians to analyze breast cancer patients for germline hereditary cancer markers at the same time as they search their blood for driver mutations.
In a conference call to discuss the firm's fourth-quarter and full-year earnings, senior management highlighted recent developments and outlined expectations for 2017.
The team found that DNA damage affects a variety of samples and may lead to erroneous low-frequency variant calls unless stringent filtering is applied or the damage is repaired prior to sequencing.
The Cancer Genome Atlas Research Network team uncovered new mutations and amplifications in their cohort of primary cervical cancers.
Biopharma revenue grew from $14.1 million to $19 million in the quarter while clinical testing revenue declined from $12 million to $9.8 million.
Both organizations plan to contribute their respective areas of expertise to work on two research projects to improve patient treatment options and outcomes.
Under the PIPseq program, Columbia University researchers sequenced the exome, transcriptome, or a gene panel in tumors of 101 high-risk pediatric cancer patients.
A small study has found that two next-generation sequencing tests that examined the same cancers uncovered different genetic alterations.
The company is planning to work with up to 40 sites, with an initial goal of sequencing circulating cell-free DNA from 10,000 people.
Based on the results, the researchers, based in Toronto, have initiated a clinical study in Ontario, called OCTANE, that involves a number of cancer centers in the province.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.